Calibre Mining Announces Loan from Directors VANCOUVER,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
45
Calibre Mining Announces Loan from Directors

VANCOUVER, British Columbia, Aug. 27, 2018 (GLOBE NEWSWIRE) -- Calibre Mining Corp. (TSX-V: CXB) (the “ Company ” or “ Calibre ”) announces that it intends to obtain an unsecured loan of $400,000 (“ Loan ”) from several directors of the Company.  The Loan will bear an annual interest of 7.0% and will be payable in cash every quarter.  The term of the Loan is 18 months from the closing date (“ Maturity Date ”) and the Loan will be due in full on the Maturity Date.  The Company may prepay the Loan, in whole or in part, at any time prior to the Maturity Date.

The Company will, subject to TSX Venture Exchange approval, issue that number of common shares of the Company to each Lender as is equal to 20% of the Loan amount advanced by such Lender divided by the “ Market Price ” of the Company’s common shares on the date that the proposed Loan is publicly announced by the Company (the “ Bonus Shares ”).  The term, “ Market Price ,” will follow the meaning prescribed under TSX Venture Exchange Policy 1.1 – Interpretation.  The Company will issue 1,333,333 common shares at a deemed price of $0.06 per common share to the Lenders as Bonus Shares.

The Company will use the proceeds of the Loan for general working capital purposes. 

As insiders of the Company are participating in the Loan and receiving Bonus Shares, the issuance of such Bonus Shares to the insiders (the “ Insider Participation ”) will be considered to be a related party transaction within the meaning of TSX Venture Exchange Policy 5.9 and Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“ MI 61-101 ”).  The Company intends to rely on the exemptions from the valuation and minority shareholder approval requirements of MI 61-101 contained in Sections 5.5(b) and 5.7(1)(a) of MI 61-101 in respect of any Insider Participation.

All Bonus Shares issued pursuant to the Loan will be subject to a hold period expiring four months and a day following the date of issue.  All dollar figures in this press release are in Canadian currency.

About Calibre Mining Corp . Calibre owns a 100% interest in over 413 km 2 of mineral concessions in the Mining Triangle of Northeast Nicaragua including the Primavera Gold-Copper Project and Santa Maria Gold Project.  Additionally, the Company has a Joint Venture with IAMGOLD (176 km 2 ) and optioned to Centerra Gold (253 km 2 ) concessions covering an aggregate area of 429 km 2 and is party to a joint venture on the 33.6 km 2 Rosita D gold-copper-silver project with Rosita Mining Corporation.  Major shareholders of Calibre include gold producer B2Gold Corp, Pierre Lassonde and management.

Calibre Mining Corp.

“Greg Smith”

Greg Smith, P.Geo. President and CEO

For further information contact: Ryan King 604 628-1012 www.calibremining.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward Looking Statements

This news release contains certain forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as “expects” or “does not expect”, “is expected”, “anticipates” or “does not anticipate” “plans”, “estimates” or “intends” or stating that certain actions, events or results “ may”, “could”, “would”, “might” or “will” be taken, occur or be achieved) are not statements of historical fact and may be “forward-looking statements”.  Forward-looking statements are subject to a variety of risks and uncertainties which could cause actual events or results to materially differ from those reflected in the forward-looking statements.

Safe Harbor Statement under the United States Private Securities Litigation Reform Act of 1995:  Except for the statements of historical fact contained herein, the information presented constitutes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.  Such forward-looking statements including but not limited to those with respect to the price of gold, potential mineralization, reserve and resource determination, exploration results, and future plans and objectives of the Company involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievement of Calibre to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.  There can be no assurance that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements.  Accordingly, readers should not place undue reliance on forward-looking statements.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CaliberMRI Revolutionizes Preclinical MRI with New Phantom

Updated Category News Views 107

CaliberMRI: Pioneers Shaping the Future of MRI Hot off the press, folks—CaliberMRI, known for setting the bar high in MRI standardization, has unleashed a new beast on the scene. Enter Model 340, a preclinical quantitative MRI phantom, ready to knock the socks off high-field systems. They’re talking 4.7T, 7T, and a jaw-dropping 9.4T compatibility here. This isn't just...

Continue Reading
LINE-X Seeks Veterans to Propel Franchise Growth

Updated Category News Views 55

If you've ever wondered about the intersection of military discipline and entrepreneurial spirit, LINE-X is handing veterans the keys, quite literally. With a nod to leathernecks and GIs, they're slashing their franchise fee by 25% for U.S. veterans aiming to trade sergeants' stripes for business clout. Franchising for Veterans: A Tailored Offer So, the word on the street...

Continue Reading
Peanuts and Diabetes: A Surprising Health Link

Updated Category News Views 68

A Nutty Approach to Diabetes Prevention Who would've thought peanuts could pack such a punch against diabetes? Amid the usual suspects of healthy foods, it's these humble legumes that are making headlines. The Peanut Institute, backed by fresh research, is shining a spotlight on their potential role in preventing type 2 diabetes, a disease that's affecting roughly 40...

Continue Reading
Untapped $41B VA Loan Potential: Opportunities Missed

Updated Category News Views 106

VA Loans: Unused Potential Sits at $41 Billion Are you telling me we're leaving $41 billion just sitting on the table in the form of untapped VA loans? That's the figure staring us in the face according to Veterans United's latest analysis. It's not just about numbers; it's a head-scratcher given the growing VA loan market share, which hit 10% last year. Where's the...

Continue Reading
Key Insights Await in Sectra's Six-Month Report

Updated Category News Views 75

Sometimes the anticipation of a financial report presentation feels akin to waiting for a storm to pass or the sun to finally break through after what seems like endless rain. That’s the kind of vibe we're getting from Sectra's upcoming six-month report presentation. Slated for November 25, President Torbjörn Kronander and CFO Jessica Holmquist will be stepping up to...

Continue Reading
AI Shakes Up Boat Discovery: Traffic Soars for Leaders

Updated Category News Views 28

AI's Surge in the Boating World Well, look who’s riding the AI wave—it's our old friends at Boat Trader and YachtWorld, leaving the competition coughing in their slipstream. Similarweb data throws some cold, hard fish onto the deck, showing these two raking in over 17 times the AI-referred traffic compared to their closest peers. If you’re sniffing around for where...

Continue Reading
Accro's Vitiligo Trial Moves Fast with Fosun's Boost

Updated Category News Views 112

Launching into Vitiligo Treatment Trials I'll tell you, the biotech world isn't for the faint-hearted, especially when you're juggling hefty terms like 'TYK2/JAK1'. But here we are, watching Accro Bioscience and Fosun Pharma dive headlong into the vitiligo space with this Phase II/III trial of AC-201. They've bagged the IND clearance, and now the first patient is in the...

Continue Reading
CPC Biotech Debuts Quattroflow HTX Pump Drive

Updated Category News Views 51

Innovative Moves in Bioprocessing Let's get one thing clear right off the bat—CPC Biotech, part of Dover (NYSE: DOV), just sent a signal loud and clear with their new Quattroflow HTX all-in-one pump drive. With a slick touchscreen, flexible control options, and self-touting accuracy, this thing sounds like it's set to change the game for biopharmaceutical processing....

Continue Reading
AI Adoption Institute Targets ROI with Peer Circles

Updated Category News Views 73

Transforming AI from Cost to Profit Alright folks, we all know AI's the flashy tool everyone's jumping on like it's the latest tech bandwagon. But here’s the raw deal: most of these shiny AI investments ain't paying back a damn thing. Enter the AI Adoption Institute (AiAi)—a new player in Denver aiming to salvage this mess and make AI about actual returns. Peering...

Continue Reading
Bramshill Fund Takes Top Spot in 2026 Fund Awards

Updated Category News Views 78

Another Feather in Bramshill's Cap They've done it again, folks. The Bramshill Multi-Strategy Income Fund has just snagged the 40 Act Fund of the Year award at the 2026 Hedge Fund Performance Awards. This ain't just another plaque for the wall; it's a nod to some serious heavy lifting by the folks handling this beast of a portfolio. The award, dished out by With...

Continue Reading

Top 5 Most Recently Viewed Articles

Twilio's Q4 Results Spark Diverse Analyst Reactions

Updated Category News Views 232

Twilio Inc Fourth Quarter Overview Twilio Inc reported notable financial results for the fourth quarter, capturing the attention of several analysts within the market. The company’s performance has sparked diverse reactions, particularly regarding its future guidance and the evolving role of artificial intelligence within its operations. Market Response to Q4 Earnings...

Continue Reading
FHLBank Indianapolis Dividends for Second Quarter of 2025

Updated Category News Views 180

FHLBank Indianapolis Declares Second Quarter Dividends FHLBank Indianapolis recently announced its second quarter dividends for 2025, detailing robust financial strategies and growth, as reflected in the declared dividends on Class B-2 activity-based capital stock and Class B-1 non-activity-based stock. These dividends have been set at annualized rates of 9.50% and 4.50%,...

Continue Reading
Neurogen Biomarking Partners with Quanterix for Alzheimer's Testing

Updated Category News Views 255

Revolutionizing Alzheimer's Detection with Neurogen Biomarking Neurogen Biomarking is making significant strides in the healthcare landscape by introducing a pioneering blood test aimed at the early detection of Alzheimer's disease and Mild Cognitive Impairment (MCI). This innovative approach leverages advanced biomarker technology developed by Quanterix Corporation,...

Continue Reading
Kepler Robotics Launches Innovative Humanoid Robot for Industries

Updated Category News Views 296

Revolutionizing Industries with the K2 Bumblebee Shanghai Kepler Robotics Co., Ltd has excitedly announced the commencement of mass production of its K2 "Bumblebee" model, confirming that the world's first commercially available hybrid-architecture humanoid robot is now shipping to eager customers. Milestone in Humanoid Robotics This significant development not only marks...

Continue Reading
Syntara Limited Reveals Groundbreaking Data in Myelofibrosis Trials

Updated Category News Views 259

Positive Interim Data from Syntara's Clinical Trials Syntara Limited, known for its innovative approach in drug development, has unveiled promising interim data concerning its ongoing Phase 2 study of SNT-5505. This clinical trial focuses on myelofibrosis, a complex bone marrow disorder that often leads to severe health complications. Details of the Clinical Trial The...

Continue Reading